

DIAGNOS will start a clinical trial study in the USA commencing December 6th, 2021 for early detection and prevention of Stroke using CARA-STROKE.

written by Raj Shah | November 23, 2021

November 23, 2021 ([Source](#)) – Diagnos Inc. (“**DIAGNOS**” or the “**Company**”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues, announces today the beginning of a clinical trial study with CommonSpirit Health Research Institute, Chattanooga Center for Neurologic Research LLC and conducted at the CommonSpirit Hospital in Chattanooga, to confirm early Proof-of-Concept results that showed a strong potential in the early detection of stroke through the inspection and analysis of the retina, as mentioned in its press release dated 2021-07-20.

The clinical trial will be carried out under the direction of Thomas G Devlin M.D., PhD. The IRB study has been approved by an Institutional Review Board (“IRB”) in compliance with all applicable regulations in the USA.

DIAGNOS will be starting the clinical trial the week of December 6th, DIAGNOS will be seeking to demonstrate that CARA-ST (CARA STROKE) will be able to predict the early signs of the condition leading to a stroke, based on the micro circulation analysis of the retina image of the patient.

As per CDC-The Center for Disease Control and Prevention, stroke causes 1 out of every 20 deaths, the management of stroke represents a cost of around **USD 34 billion** per year in the United States. Hence, early diagnosis and treatment to prevent deaths from stroke is a time sensitive necessity.

According to the World Health Organization, 15 million people suffer a **stroke worldwide** each year. Of these, 5 million die and another 5 million are permanently disabled. High blood pressure contributes to more than 85% of **strokes worldwide**. **Europe** averages approximately 650,000 **stroke** related deaths each year.

“According to new reports published by Worldwide Research Institutes, the worldwide market size for Stroke Management will hit over \$66 Billion dollars by 2023. DIAGNOS intends to be part of the solution by making available an affordable predictive test to the general public,” said **Mr. André Larente, President of DIAGNOS**.

“This year our new stroke management application will be field tested in multiple countries. For our investors this ground-breaking test comes at an ideal time in terms of shareholder value creation as the combination of both CARA-DR and CARA-ST tools will be transformational in helping to monitor the health of existing and future patients with cardiovascular disease,” said Mr. Andre Larente, President of DIAGNOS.

About CommonSpirit

CommonSpirit Health is a non for profit, Catholic health system dedicated to advancing health for all people. It was created in February 2019 through the alignment of Catholic Health initiatives and Dignity Health. With a team of approximately 125,000 physicians and advanced practice clinicians. CommonSpirit Health operates 137 hospitals and more than 1,000

care sites across 21 states. In FY2020, Catholic Health initiatives and Dignity Health had combined revenues of nearly \$29.6 billion and provided \$4.6 billion in charity care, community benefit and unreimbursed government programs.

About DIAGNOS

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.diagnos.com and www.sedar.com

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Data

For further information, please contact:

Mr. André Larente, President

DIAGNOS Inc.

Tel: 450-678-8882 ext. 224

Corporate Communications:

Nancy Massicotte

IR Pro Communications Inc.

Dir: +1 604-507-3377 TF: 1-866-503-3377

Email: